Physician profile
Theodore Morgan
NPI 1861602443
$8,474.93
in general payments reported to CMS, 2019-2025
31 companies · $1,399 in 2025
The $1,399 reported for 2025 was more than what 85% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $781 · 2020: $570 · 2021: $1,087 · 2022: $1,964 · 2023: $1,304 · 2024: $1,369 · 2025: $1,399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,955 · Education: $117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,954.68 |
| Education | $117.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $1,157.62 | 2020-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $732.86 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $616.39 | 2019-2025 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Abbvie INC. | $562.18 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $544.95 | 2019-2025 | Trintellix |
| Supernus Pharmaceuticals, INC. | $532.09 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $506.62 | 2021-2025 | Azstarys |
| Lundbeck LLC | $411.63 | 2019-2024 | Rexulti |
| Neuronetics, INC. | $398.14 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $392.74 | 2019-2024 | Spravato, Invega Sustenna, Invega Trinza |
| Sunovion Pharmaceuticals INC. | $334.23 | 2019-2022 | |
| Neurocrine Biosciences, INC. | $294.10 | 2021-2025 | Ingrezza |
| Alkermes, INC. | $283.77 | 2019-2025 | Aristada, Lybalvi |
| Neos Therapeutics, Lp | $222.93 | 2019-2024 | Adzenys Xr-Odt |
| Idorsia Pharmaceuticals US INC | $209.41 | 2022-2024 | Quviviq |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $197.46 | 2023-2025 | Auvelity |
| Ironshore Pharmaceuticals INC. | $162.38 | 2019-2024 | |
| Vanda Pharmaceuticals INC. | $149.25 | 2022-2025 | Fanapt |
| Bausch Health US, LLC | $129.08 | 2021-2025 | Aplenzin, Wellbutrin |
| Tris Pharma INC | $96.32 | 2019-2023 | Dyanavel Xr |
| Adlon Therapeutics L.P. | $91.59 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $83.36 | 2020-2023 | Belsomra |
| Noven Therapeutics, LLC | $78.70 | 2023-2024 | Xelstrym, Secuado |
| Owp Pharmaceuticals, INC. | $67.16 | 2019-2021 | |
| Shire North American Group INC | $64.39 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $42.47 | 2024-2025 | Cobenfy |
| Vertical Pharmaceuticals, LLC | $30.47 | 2019 | |
| Collegium Pharmaceutical, INC. | $24.85 | 2025 | Jornay Pm |
| Noven Pharmaceuticals, INC. | $23.52 | 2024 | Xelstrym |
| Almatica Pharma LLC | $20.70 | 2024 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $13.57 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Morgan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.